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Abstract
Introduction Macrophage migration inhibitory factor (MIF) plays
an essential pathophysiological role in septic shock, but its role
in central nervous system infection (CNS) remains to be defined.
Methods We investigated cerebrospinal fluid (CSF) levels of
MIF in 171 patients who were clinically suspected of having
meningitis on admission. Of these, 31 were found to have
purulent meningitis of known aetiology, 20 purulent meningitis of
unknown aetiology, 59 lymphocytic meningitis and 11
encephalitis, whereas 50 were suspected of having but had no
evidence of CNS infection.
Results CSF MIF levels were significantly higher in patients with
purulent meningitis of known aetiology (median [interquartile
range]: 8,639 [3,344 to 20,600] ng/l) than in patients with
purulent meningitis of unknown aetiology (2,209 [1,516 to
6,550] ng/l; Mann-Whitney test, P  = 0.003), patients with
lymphocytic meningitis (1,912 [1,302 to 4,105] ng/l; P < 0.001)
and patients suspected of having but without evidence of CNS
infection (1,472 [672 to 3,447] ng/l; P < 0.001). Also, patients
with encephalitis (6,937 [3,961 to 8,353] ng/l) had higher CSF
MIF than did patients without CNS infection (P < 0.01). Among
patients with purulent meningitis, CSF MIF levels were
significantly higher in patients infected with pneumococci than
in those with meningococcal infection (11,569 [8,615 to
21,935] ng/l versus 5,006 [1,717 to 10,905] ng/l; P = 0.02), in
patients who required versus those not requiring assisted
ventilation (10,493 [5,961 to 22,725] ng/l versus 3,240 [1,563
to 9,302] ng/l; P = 0.003), and in patients with versus those
without impaired consciousness (8,614 [3,344 to 20,935] ng/l
versus 2,625 [1,561 to 7,530] ng/l; P = 0.02). CSF MIF levels
correlated significantly with meningeal inflammation (P < 0.05)
but not with systemic inflammatory response (P  > 0.05) in
patients with purulent meningitis of known aetiology, those with
lymphocytic meningitis and those with encephalitis.
Conclusions MIF was significantly increased in the CSF of
patients with purulent meningitis and encephalitis, and was to
some degree associated with severity of the infection. Our
findings indicate that MIF may play an important role in CNS
infection.
Introduction
Macrophage migration inhibitory factor (MIF) is a cytokine that
participates in both innate and adaptive immune responses. It
is released from a wide range of cells, including macrophages
and T lymphocytes, and when released it counter-regulates
the inhibitory effect of corticosteroids on the release of pro-
inflammatory cytokines from lipopolysaccharide-stimulated
monocytes. This suggests a role of MIF in both the initiation of
and sustaining the inflammatory cascade (for review see
[1,2]). The role played MIF has been described extensively in
sepsis, in which serum levels of MIF were found to be
increased in septic patients and correlated with both disease
severity and mortality [3-5]. Moreover, injection of MIF
increased mortality in experimental sepsis, whereas inhibition
of MIF decreased mortality [3,6], emphasizing the critical
involvement of MIF in the pathophysiology of septic shock.
Bacterial meningitis is characterized by an overwhelming
inflammatory cascade, primarily localized to the subarachnoi-
dal space, which continues to evolve after eradication of the
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bacterial pathogen by antibiotic therapy [7]. Anti-inflammatory
therapy with corticosteroids is beneficial in bacterial meningi-
tis [8], suggesting that MIF may also influence the course of
central nervous system (CNS) infections. Cerebrospinal fluid
(CSF) levels of various inflammatory mediators have to some
degree been useful as diagnostic and prognostic markers in
meningitis [9-11]. Screening pooled CSF samples with micro-
array analysis for several mediators of the host immune
response [12] revealed that MIF was upregulated in patients
with purulent meningitis as compared with uninfected control
individuals, indicating that MIF could be a potential new candi-
date for future meningitis studies. Moreover, MIF were ele-
vated in CSF from patients with encephalitis due to West Nile
virus [13] or with various neurological diseases such as multi-
ple sclerosis [14] and Alzheimer's disease [15]. Furthermore,
inhibition of MIF protected mice from brain disease due to
West Nile virus [13] or autoimmune encephalomyelitis
[16,17], further suggesting that MIF plays a pathophysiologi-
cal role in CNS infection.
The aim of the present study was to investigate CSF MIF levels
in 171 patients clinically suspected of having meningitis on
admission and to study the use of CSF MIF in the differential
diagnosis of meningitis and as a prognostic factor.
Materials and methods
Study design
Since 1988 CSF samples have been collected prospectively
from patients undergoing lumbar puncture at the Department
of Infectious Diseases at Hvidovre University Hospital. All lum-
bar punctures were performed as routine diagnostic proce-
dures and were done in accordance with the hospital's ethical
standards. Immediately after lumbar puncture, all CSF sam-
ples were transported directly to the Department of Clinical
Biochemistry, where they were centrifuged, and the superna-
tants were collected and stored at -20°C within 15 to 30 min-
utes. The following day, CSF samples were registered and
transferred for storage at -80°C. Because of the non-interven-
tional nature of the study, blood samples were not routinely
collected together with the CSF sampling. However, in six
patients a blood sample was available that was obtained on
admission and at the same time as the CSF sample. All proto-
cols were approved by the local scientific ethics committee
and the Danish Data Protection Agency (1995–1200/95–
517); because the study required no intervention in addition to
routine care, informed consent from patients was not required.
Patients' demographic and clinical characteristics, as well as
biochemical and microbiological data, were obtained retro-
spectively from medicals records. All patients who were clini-
cally suspected of having meningitis, in whom CSF samples
was available that had been obtained at admission from a diag-
nostic lumbar puncture conducted during the period from
1988 to 2002, were included, except patients infected with
HIV or Mycobacterium tuberculosis infection.
A total of 205 patients were identified. However, 34 patients
(13 patients with purulent meningitis, 10 with lymphocytic
meningitis, two with encephalitis and nine without CNS infec-
tion) were excluded, because MIF could not be measured for
lack of CSF. Thus, the study comprised 171 patients. Based
on clinical, microbiological and biochemical characterization,
patients could be divided into five diagnostic groups.
The first group included those with purulent meningitis of
known bacterial aetiology (n = 31). Twenty-five patients had
positive CSF Gram stain or CSF culture (CSF white blood cell
[WBC] count, median [range]: 3,857 [16 to 21,745] cells/μl)
and six had neutrophil pleocytosis (CSF WBC count: 2,165
[16 to 18,485] cells/μl) and positive blood culture or a signifi-
cant increase in antibody titres against Neisseria meningitidis.
Fifteen cases were due to N. meningitidis, 11 to Streptococ-
cus pneumoniae, two to Haemophilus influenzae, one to
Klebsiella pneumoniae, one to Staphylococcus aureus and
one to Listeria monocytogenes.
Patients in the second group, purulent meningitis of unknown
bacterial aetiology (n = 20), had negative CSF and blood cul-
tures, neutrophil pleocytosis (CSF WBC count: 359 [63 to
6,567] cells/μl, with > 80% neutrophils, except for one patient
with 1,210 cells/μl and 45% neutrophils), who were treated
for bacterial meningitis in accordance with local recommenda-
tions.
Five of the 20 patients (20%) with negative cultures and one
out of the 31 patients (3%) with known bacterial aetiology had
CSF WBC count under 1,000 cells/μl, CSF/blood glucose
ratio above 0.3, CSF protein levels under 1 g/l and blood
WBC count under 12 × 109 cells/l. Antibiotic therapy was ini-
tiated before the lumbar puncture in 23% (7/31) of patients
with purulent meningitis of known bacterial aetiology and in
15% (3/20) of those with an unknown bacterial aetiology. The
initial or empirical antibiotic therapy for purulent meningitis
was intravenous ceftriaxone and ampicillin. If bacteria were
demonstrated in the CSF and/or blood, then antibiotic therapy
was changed in based on the susceptibility profile of the path-
ogen. The duration of antibiotic therapy was usually 7 to 10
days.
The third group included patients with lymphocytic meningitis
(pleocytosis with a predominance of mononuclear cells; n =
59). All of these cases were due to acute aseptic meningitis.
A known viral aetiology was established in 15 cases (enterovi-
rus in 14 and herpes simplex virus-2 in one). The majority of
patients recovered fully without antibiotic treatment, except for
14 patients who received one dose of antibiotics immediately
after the lumbar puncture was performed and before the
results of the CSF analysis were known (usually < 30 minutes
after lumbar puncture). Two patients also received one dose
of aciclovir.Available online http://ccforum.com/content/13/3/R101
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The fourth group included patients with encephalitis (altered
consciousness, abnormal electroencephalogram and/or com-
puted tomography/magnetic resonance scan; n = 11). A viral
aetiology was established in two cases (herpes simplex virus
and varicella zoster virus [VZV]). All patients were treated with
aciclovir (median 10 days, range 6 to 14 days).
The fifth diagnostic group included patients suspected of hav-
ing meningitis but without evidence of CNS infection (no CSF
pleocytosis; n = 50). Four patients had septic shock (in three
this was due to N. meningitidis and in one it was due to
Escherichia coli), seven had pneumonia, three had acute ton-
sillitis, one had acute otitis media, two had urinary tract infec-
tion, one had hepatitis due to cytomegalovirus, 25 patients
had fever of unknown origin and seven had cephalgia.
Cerebrospinal fluid analysis
CSF samples were analyzed by routine laboratory methods to
determine glucose and protein levels, total leucocyte count
and differential count.
Measurement of MIF
MIF levels wee measured using a commercial available ELISA
(R&D Systems, Inc. Minneapolis, MN, USA), in accordance
with the manufacturer's instructions. In brief, MaxiSorp plates
(Nunc, Roskilde, Denmark) were coated and incubated over-
night at 4°C with a murine monoclonal anti-MIF antibody (R&D
Systems), diluted in phosphate-buffered saline (PBS; Statens
Serum Institut, Copenhagen, Denmark) to a final concentration
of 2 μg/ml. After the plates were washed three times with
wash buffer (PBS with Triton X-100), the unbound sites were
blocked by adding 300 μl blocking buffer (PBS with 1%
bovine serum albumin and 5% sucrose) for 90 minutes at
room temperature. After another three washes, standards
(recombinant human MIF [R&D Systems] in triplicates) or CSF
and blood samples (at least in duplicate) diluted in dilution
buffer (Tris-buffered saline with 0.1% bovine serum albumin
and 0.05% Tween; Statens Serum Institut) were added and
incubated for 2 hours at room temperature. After another three
washes, MIF was detected by adding a biotinylated goat anti-
human MIF antibody (R&D Systems) diluted in dilution buffer
to a final concentration of 0.2 μg/ml and incubating for 2 hours
at room temperature. After washing five times, streptavidin
horseradish peroxidase (R&D Systems) diluted 1:1,000 in
dilution buffer was added and incubated for 20 minutes at
room temperature with subsequent washing five times and
adding substrate solution, tetramethylbenzidine (KEM EN TEC
Diagnostics, Taastrup, Denmark), for 30 minutes. The reaction
was stopped with 1.2 mol/l H2SO4; Statens Serum Institut),
and optical density at 450 nm was read on an ELISA reader.
Lower limit of detection was 20 pg/ml.
Statistical analysis
All data are expressed as medians and interquartile ranges.
For continuous data, comparisons between two groups were
performed using the Mann-Whitney test, whereas the Kruskal-
Wallis test was used for comparisons between more than two
groups. Fisher's exact test was used for comparisons between
categorical data. When appropriate, correction with a Bonfer-
roni's coefficient of 10 was used to compensate for multiple
comparisons between the five diagnostic groups. For correla-
tion analysis, the nonparametric Spearman's test was used. P
< 0.05 were considered statistically significant.
Results
Clinical and demographic data for 171 patients in whom 
cerebrospinal fluid samples were taken on admission
Clinical and demographic data for the 171 patients with avail-
able CSF samples on admission are shown in Table 1. Twelve
patients died during hospitalization (four with S. pneumoniae
meningitis, one with N. meningitidis meningitis, one with S.
aureus meningitis, one with K. pneumoniae meningitis, one
with purulent meningitis of unknown aetiology, two with
encephalitis of unknown aetiology, and two without meningitis
[meningococcaemia and pneumonia]).
Levels of macrophage migration inhibitory factor in 
cerebrospinal fluid at admission
A total of 163 patients had measurable CSF MIF levels,
whereas eight patients had MIF levels under 20 ng/l. There
was a significant difference between the five diagnostic
patient groups (Kruskal Wallis test, P < 0.0001; Figure 1).
Significantly higher CSF MIF levels were detected in patients
with purulent meningitis of known aetiology (8,639 [3,344 to
20,600] ng/l) than in those with purulent meningitis of
unknown aetiology (2,209 [1,516 to 6,550] ng/l; Mann Whit-
ney test, P = 0.003), those with lymphocytic meningitis (1,912
[1,302 to 4,105] ng/l; P < 0.001) and those suspected of hav-
ing meningitis but without evidence of CNS infection (1,472
[672 to 3,447] ng/l; P < 0.001). Also, patients with encepha-
litis (6,937 [3,961 to 8,353]) had significantly higher CSF MIF
levels than did those with lymphocytic meningitis (P = 0.004)
and patients without meningitis (P  < 0.001). Moreover,
patients with pneumococcal meningitis had significantly
higher CSF MIF levels than did those with meningococcal
meningitis (11,569 ng/l [8,615 to 21,935] ng/l versus 5,006
[1,717 to 10,905] ng/l; P = 0.02). Before lumbar puncture,
two out of 171 patients – one with pneumococcal meningitis
(CSF MIF level 51,539 ng/l) and one with VZV encephalitis
(CSF MIF level 5,042 ng/l) received therapy with prednisolone
5 mg/day for treatment of rheumatoid arthritis and chronic
myeloid leukaemia, respectively.
Relation between MIF levels in CSF and blood
One patient with VZV encephalitis had approximately fivefold
higher MIF levels in CSF than in blood (5,042 ng/l versus
1,031 ng/ml), and one patient with pneumococcal meningitis
with accompanying bacteraemia had lower MIF levels in CSF
than in blood (8,615 ng/l versus 10,913 ng/l). Three patients
without CNS infection had lower MIF levels in CSF than inCritical Care    Vol 13 No 3    Østergaard and Benfield 
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Table 1
Clinical and biochemical characteristics of 171 patients suspected of having meningitis on admission
Purulent meningitis of known 
aetiology 
(n = 31)
Purulent meningitis of 
unknown aetiology 
(n = 20)
Lymphocytic meningitis (n 
= 59)
Encephalitis 
(n = 11)
No CNS infection 
(n = 50)
Female sex 45% (14/31) 50% (10/20) 41% (24/59) 45% (5/11) 48% (24/50)
Age (in years) 20 (10–53) (31/31) 23 (7–30) (20/20) 25 (17–31)‡ (59/59) 55 (46–64) (11/11) 28 (10–44) (50/50)
Underlying illness* 23%† (7/31) 10% (2/20) 2% (1/59) 0% (0/11) 4% (2/50)
Body temperature (°C) 38.8 (38.4–39.6)† (27/31) 38.3 (38.0–39.2) (18/20) 38.1 (37.7–38.7) (49/59) 37.8 
(37.1–38.9) (9/11)
39 
(37.5–39.6) (37/50)
Mean arterial pressure 
(mmHg)
93 (87–117) (22/31) 90 (79–106) (12/20) 90 (82–100) (42/59) 102 
(86–115) (10/11)
93 (77–103) (30/50)
Heart rate 
(beats/minute)
113 (98–129)†‡ 
(20/31)
90 (80–108) (16/20) 88 (73–100) (44/59) 80 (70–101) (10/11) 100 
(85–120) (30/50)
Septic shock 16%† (5/31) 0% (0/20) 0% (0/59) 0% (0/11) 8% (4/50)
Back rigidity 80%* (24/30) 95%‡§ (18/19) 88%‡§ (51/58) 40% (4/10) 57% (26/46)
Decreased 
consciousness
66%*†§ (19/29) 22%†‡ (4/18) 0%‡ (0/57) 91%§ (10/11) 13% (6/46)
Assisted ventilation 45%*†§ (14/31) 0% (0/20) 0% (0/59) 20% (2/10) 10% (5/50)
Steroid therapy 35%*†§ (11/31) 0% (0/20) 0% (0/59) 10% (1/10) 0% (0/50)
Fatal outcome 23%† (7/31) 5% (1/20) 0% (0/59) 18% (2/11) 4% (2/50)
Days in hospital 
(survivors)
11 (9–15)†§ (24/24) 9 (8–12)†§ (19/19) 4 (2–5)‡ (59/59) 12 (11–30)§ (9/9) 4 (2–7) (48/48)
CSF WBC count (× 106 
cells/l)
3380 (767–6,528)*†‡§ (31/31) 359 (128–1,066)‡§ 
(20/20)
139 (61–366)§ 
(59/59)
57 (13–102)§ 
(11/11)
1 (1–2) (50/50)
CSF PMNs (× 106 cells/l) 2,727 (398–5,404)*†‡§ (30/31) 305 (112–600)†‡§ (20/20) 25 (7–75)§ (56/59) 5 (2–29)§ (9/11) < 1
CSF mononuclear 
(× 106 cells/l)
248 (38–523)§ 30/31 16 (6–93)§ (20/20) 74 (25–327)§ 
(56/59)
79 (25–106)§ (9/11) < 1
CSF glucose (mmol/l) 2.2 (0.6–3.5)†§ 
(30/31)
3.3 (3.0–3.7)§ 
(17/20)
3.3 (3.0–3.6)§ 
(56/59)
3.1 (2.7–3.9) (10/11) 3.7 (3.4–4.5) (48/50)
CSF/blood glucose ratio 0.3 (0.1–0.5)*†§ 
(22/31)
0.6 (0.4–0.7) (15/20) 0.6 (0.5–0.7) (46/59) 0.5 (0.3–0.7) (8/11) 0.6 (0.6–0.8) (30/50)
CSF protein (g/l) 1.9 (1.5–4.8)*†§ 
(30/31)
0.7 (0.7–1.4)§ 
(20/20)
0.7 (0.4–1.3)§ 
(54/59)
1.1 (0.6–1.7)§ 
(11/11)
0.3 (0.2–0.5) (47/50)
Blood WBC count 
(× 109 cells/l)
21.7 (14.1–24.4)†‡§ (31/31) 14.4 (8.3–16.8)† 
(20/20)
8.8 
(7.3–10.9) (59/59)
7.4 (6.9–9.6) (9/11) 9.0 
(6.2–12.8) (48/50)
Blood PMNs 
(× 109 cells/L)
17.1 (12.5–21.5)*†‡§ (30/31) 10.9 (7.0–15.0)†§ (20/20) 6.8 (5.3–8.5) (58/59) 4.5 (4.1–9.2) (4/11) 6.0 (4.5–9.6) (39/50)
Blood lymphocytes 
(× 109 cells/L)
1.1 (0.7–1.5) (30/31) 1.4 (1.1–1.8) (20/20) 1.5 (1.0–1.9) (58/59) 1.7 (0.8–2.1) (4/11) 1.3 (0.8–2.1) (38/50)
Blood monocytes 
(× 109 cells/l)
0.7 (0.4–1.0)† 
(30/31)
0.6 (0.4–0.9) (20/20) 0.4 (0.3–0.6) (58/59) 0.6 (0.3–0.9) (4/11) 0.4 (0.3–0.8) (38/50)
Platelets (× 109 cells/l) 235 
(166–286) (31/31)
286 
(215–370) (20/20)
254 
(210–310) (56/59)
231 
(174–351) (9/11)
230 
(168–275) (47/50)
Sodium (mmol/l) 136 
(135–138) (30/31)
136 
(133–139) (20/20)
138 
(136–140) (59/59)
130 
(127–140) (8/11)
138 
(136–141) (43/50)
Potassium (mmol/l) 3.6 (3.3–3.9)† 
(29/31)
3.8 (3.6–4.1) (19/20) 3.9 (3.7–4.2) (59/59) 4.0 (3.9–4.1) (7/11) 3.9 (3.4–4.3) (44/50)
Creatinine (μmol/l) 76 (54–85) (30/31) 58 (46/72) (18/20) 75 (55–85) (56/59) 83 (73–100) (7/11) 71 (49–87) (45/50)
Factors II, IIV and X 0.57 (0.4–0.7)† 
(28/31)
0.92 
(0.7–1.0) (11/20)
0.78 
(0.7–1.0) (36/59)
0.73 (0.6–1.0) (7/11) 0.74 
(0.5–0.9) (31/50)
Arterial PO2 (kPa) 11.0 
(9.0–13.0) (15/31)
12.3 
(10.7–13.8) (7/20)
8.5 (7.8–11.5) (3/59) 5.2 (1/11) 12.7 
(8.0–15.0) (6/50)
Positive blood culture 62%*†‡§ (18/29) 0% (0/20) 0% (0/59) 0% (0/10) 6% (3/48)
Values are expressed as percentage or median (interquartile range) (n/n evaluated). For continuous data Kruskal Wallis test with subsequent Mann-
Whitney test was used; for categorical data Fisher's exact test was employed. When appropriate, correction for multiple comparisons with a 
Bonferroni coefficient of 10 was applied. *P < 0.05 versus purulent meningitis of unknown aetiology; †P < 0.05 versus lymphocytic meningitis; ‡P < 
0.05 versus encephalitis; §P < 0.05 versus non-meningitis. aFor example, malignancy, diabetes, drug abuse or alcoholism. CSF, cerebrospinal fluid; 
PMN, polymorphonuclear leucocyte; PO2, partial oxygen tension; WBC, white blood cell.Available online http://ccforum.com/content/13/3/R101
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blood (one patient with pneumonia [2,660 ng/l versus 4,955
ng/l, respectively] and two with fever of unknown origin [366
ng/l versus 1,371 ng/l and 83 ng/l versus 1,864 ng/l]),
whereas one patients with hepatitis due to cytomegalovirus
had higher MIF levels in CSF than in blood (1,989 ng/l versus
207 ng/l).
Associations of CSF MIF levels with clinical features
Purulent meningitis
Among patients with purulent meningitis, CSF MIF levels were
to some degree associated with severity of the infection. CSF
MIF levels were significantly higher in patients who required
assisted ventilation than in those who did not (10,493 [5,961
to 22,725] ng/l versus 3,240 [1,563 to 9,302] ng/l; P  =
0.003), and in patients with impaired consciousness than in
those without (8,614 [3,344 to 20,935] ng/l versus 2,625
[1,561 to 7,530] ng/l; P = 0.02). However, CSF MIF levels
were not significantly higher in patients who died from the
infection than in surviving patients (6,662 [3,383 to 17,855]
ng/l versus 5,006 [1,701 to 10,971] ng/l, respectively; P >
0.05) or in patients who developed septic shock than in those
who did not (5,161 [3,830 to 25,474] ng/l versus 5,617
[1,693 to 10,922] ng/l; P > 0.05). In purulent meningitis of
known bacterial aetiology, the following were all associated
with high CSF MIF levels: positive Gram stain (10,905 [6,227
to 20,935] ng/l versus 2,821 [772 to 4,111] ng/l for negative
Gram stain; P = 0.006), positive CSF culture (10,905 [5,161
to 20,935] ng/l versus 2,608 [733 to 5,750] ng/l for negative
CSF culture; P = 0.008) and positive blood culture (11,270
[8,502 to 21,185] versus 4,315 [2,251 to 6,227] ng/l for neg-
ative blood culture; P = 0.006).
Encephalitis
The two patients who died from encephalitis had high CSF
MIF levels (6,937 ng/l and 14,213 ng/l), but the difference in
CSF MIF between these patients and those who survived
(5,042 [2,999 to 8,090] ng/l) was not statistically significant
(P > 0.05).
Patients suspected of meningitis but without evidence of 
CNS infection
CSF MIF levels correlated with number of days hospitalized
(rho = 0.31, P = 0.03).
Association of CSF MIF levels with biochemical 
parameters in CSF and blood
Associations between CSF MIF levels at admission and bio-
chemical parameters in CSF and blood are summarized in
Table 2. In patients with purulent meningitis of known aetiol-
ogy, in patients with lymphocytic meningitis and in patients
with encephalitis, CSF MIF levels correlated significantly with
meningeal inflammation (P < 0.05) but not with the systemic
inflammatory response (P > 0.05). In contrast, no such asso-
ciation was observed in patients with purulent meningitis of
unknown aetiology (P > 0.05). In patients without CNS infec-
tion, CSF MIF correlated significantly with CSF protein levels
(P < 0.05).
Discussion
In the present study we found that CSF MIF levels were signif-
icantly higher in patients with purulent meningitis and
encephalitis than in patients with lymphocytic meningitis and
patients suspected of having meningitis but without evidence
of CNS infection. In accordance with our findings, a previous
study [13] showed that patients with encephalitis due to West
Nile virus had elevated CSF MIF levels, compared with unin-
fected control patients. However, because of significant over-
lap in CSF MIF levels between the five diagnostic groups
identified in the present study, resulting in poor prognostic
sensitivity and specificity (data not shown), the use of CSF MIF
levels for diagnostic purposes cannot be recommended. In
particular, CSF MIF levels were not useful in differentiating
between purulent meningitis of unknown aetiology and lym-
phocytic meningitis.
CSF MIF levels were significantly higher in patients with pneu-
mococcal meningitis than in those with meningococcal menin-
gitis. Pneumococcal meningitis carries a higher mortality than
Figure 1
CSF MIF levels from patients with suspected or confirmed meningitis at  admission CSF MIF levels from patients with suspected or confirmed meningitis at 
admission. There was a significant difference between the five diagnos-
tic groups (Kruskal Wallis: P < 0.0001). Bars indicate medians. Group 
1 includes patients with purulent meningitis of known aetiology (n = 
31), group 2 purulent meningitis of unknown aetiology (n = 20), group 
3 lymphocytic meningitis (n = 59), group 4 encephalitis (n = 11) and 
group 5 no CNS infection (n = 50). P values calculated using the Mann 
Whitney test. Group 1 versus group 2 (P = 0.003) versus group 3 (P < 
0.001) versus group 4 (P = 0.2) versus group 5 (P < 0.001). Group 2 
versus group 3 (P = 0.5) versus group 4 (P = 0.04) versus group 5 (P 
= 0.055). Group 3 versus group 4 (P = 0.004) versus group 5 (P = 
0.075). Group 4 versus group 5 (P < 0.001). CSF, cerebrospinal fluid; 
MIF, macrophage migration inhibitory factor.Critical Care    Vol 13 No 3    Østergaard and Benfield 
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meningococcal meningitis, and differences in bacterial viru-
lence factors may account for higher CSF MIF levels in pneu-
mococcal meningitis than in meningococcal meningitis.
Moreover, CSF MIF levels were to some degree related to dis-
ease severity, being significantly higher levels in patients with
purulent meningitis who were unconscious or who required
assisted ventilation, but CSF MIF levels were not correlated
with mortality or presence of septic shock. Previous studies
found that serum levels of MIF were related to mortality in sep-
sis [3-5]. Unfortunately, we did not measure serum levels of
MIF in the present study, so we were unable to clarify whether
serum levels are a better prognostic marker than CSF levels.
In the present study, we found a significant correlation
between CSF MIF levels and CSF WBC count in meningitis
and encephalitis patients, whereas no association was found
between CSF MIF levels and the systemic inflammatory
response (blood WBC count). Moreover, Arjona and cowork-
ers [13] found that MIF levels were approximately 10-fold
higher in CSF than in plasma in patients with encephalitis due
to West Nile virus, indicating that MIF may be locally released
during CNS infection. Here we found a fivefold higher MIF
concentration in CSF than in blood in the only encephalitis
patient in whom we obtained corresponding CSF and blood
samples. Also corroborating the findings of previous studies
[13], in a limited number of patients with no CNS infection we
found that CSF MIF levels were lower than corresponding
blood MIF levels. In one patient with pneumococcal meningitis
and bacteraemia with a lung focus, high MIF levels were found
both in CSF and blood, suggesting that MIF may be elevated
at several sites of an infection. However, further studies should
be performed to clarify the release of MIF in CSF and blood
during meningitis.
MIF is produced by a wide range of cell types including mac-
rophages [18] and activated T cells [19]. Interestingly,
encephalitis patients had high CSF MIF levels despite a minor
CSF cellular infiltrate, as compared with meningitis patients,
which could indicate that MIF was derived from resident brain
cells rather than from CSF inflammatory cells. However, the
strongest correlation with MIF in encephalitis was found to be
for CSF polymorphonuclear leucocytes and CSF lactoferrin (a
matrix protein of polymorphonuclear leukocyte-specific gran-
ules [20]), whereas the correlation with neopterin (a marker of
CNS macrophage activation [21]) was weaker. Indeed, in a
study of cerebral malaria conducted in Malawi [22], immuno-
histochemical analysis of a few fatal bacterial meningitis cases
revealed that MIF was primarily expressed in the inflamed
meninges, to some degree in astrocytes and ependymal cells,
and less frequently in blood vessels with in the brain paren-
chyma.
Apart from its critical role in sepsis through potentiating septic
shock, MIF is a pituitary-derived antagonist of glucocorticoids
[6]. Adjunctive therapy with corticosteroids might have a ben-
eficial effect in patients with purulent meningitis who have high
CSF MIF levels. However, we found no such association in the
present study (data not shown). On the other hand, adminis-
tration of corticosteroids to rats was found to increase MIF
expression in blood [23] as well as various body tissues [24].
Only two patients were treated with glucocorticoids at the
time of lumbar puncture; thus, although both patients had high
Table 2
Association (rho values) between CSF MIF levels at admission and biochemical parameters in CSF and blood
CSF samples Purulent meningitis of 
known aetiology 
(n = 31)
Purulent meningitis of 
unknown aetiology 
(n = 20)
Lymphocytic 
meningitis (n = 59)
Encephalitis (n = 11) No CNS infection 
(n = 50)
CSF WBC count 0.49† -0.21 0.35† 0.61* 0.07
CSF PMNs 0.50† -0.20 -0.04 0.88† -0.24
CSF mononuclear 0.39* -0.44 0.37† 0.18 0.13
CSF glucose -0.55‡ 0.17 -0.04 -0.25 0.14
CSF/blood glucose -0.51* -0.22 0.12 -0.21 -0.16
CSF protein 0.42* 0.12 0.31* 0.36 0.39†
CSF lactoferrin 0.45* -0.33 0.15 0.95* 0.20
CSF neopterin 0.32 -0.14 0.33* 0.80 0.17
Blood WBC count 0.13 -0.19 -0.18 -0.50 0.06
Blood neutrophils 0.22 -0.14 -0.18 -0.40 -0.04
Blood lymphocytes -0.27 -0.29 0.04 -0.40 0.02
Blood monocytes 0.18 -0.60* -0.14 -0.40 0.11
*P < 0.05, †P < 0.01, ‡P < 0.001. CNS, central nervous system; CSF, cerebrospinal fluid; MIF, macrophage migration inhibitory factor; PMN, 
polymorphonuclear leucocyte; WBC, white blood cell.Available online http://ccforum.com/content/13/3/R101
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CSF MIF levels, further studies are required to determine the
effect of glucocorticoids on CSF MIF release during CNS
infection.
The role played by MIF has been studied extensively in experi-
mental disease models using pharmacological intervention
(stimulation with MIF or inhibition with antibodies to MIF) or by
use of MIF gene-deficient animals. Inhibition or lack of MIF
attenuated development of septic shock [3,6], encephalitis
[13], autoimmune encephalomyelitis [16,17], rheumatoid
arthritis [25,26], colitis [27], concanavalin A induced liver
injury [28], glomerulonephritis [29] and atherosclerosis [30].
Experimental meningitis studies have documented that both
the systemic and meningeal inflammatory response plays a
crucial role in the development of brain damage [7,31]. There-
fore, to explore further the role played by MIF in bacterial men-
ingitis, experimental meningitis studies with MIF intervention
are still warranted.
Conclusions
MIF levels were significantly increased in CSF of patients with
purulent meningitis of known aetiology or with encephalitis,
and they were to some degree associated with severity of the
infection. Our findings indicate that MIF may play a pathophys-
iological role in CNS infection.
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